Sulfonamide Allergy

📋 Key Information Summary

📋

Sulfonamide allergy encompasses hypersensitivity reactions to sulfonamide-class medications, most commonly sulfamethoxazole in co-trimoxazole (trimethoprim–sulfamethoxazole).
Reactions range from mild cutaneous eruptions (>90%) to severe, life-threatening conditions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
The arylamine hypothesis explains immunological reactions: metabolism of the arylamine group (present in sulfonamide antibiotics but not non-antibiotic sulfonamides) generates reactive hydroxylamine and nitroso metabolites that trigger immune responses.
Cross-reactivity risk between sulfonamide antibiotics and non-antibiotic sulfonamides (e.g., celecoxib, furosemide, thiazides) is extremely low (<1%) and generally not clinically relevant due to differing chemical structures.
True IgE-mediated (Type I) reactions to sulfonamides are uncommon; most hypersensitivity reactions are T-cell-mediated (Type IV), typically occurring 7–14 days after initiation.
Delayed maculopapular exanthem is the most frequent presentation; fixed drug eruptions, urticaria, and serum sickness-like reactions also occur.
Desensitisation protocols are available for patients requiring co-trimoxazole, particularly for Pneumocystis jirovecii prophylaxis in immunocompromised patients.
Co-trimoxazole is the first-line agent for several Australian conditions including uncomplicated UTI and Pneumocystis prophylaxis — confirmed allergy necessitates documented alternative regimens.
Skin prick and intradermal testing for sulfonamides have limited sensitivity and are not routinely recommended in Australian allergy practice.
All reactions must be clearly documented in the patient's medical record, the Australian Immunisation Register (where applicable), and My Health Record.
Risk factors for severe reactions include HIV infection, slow acetylator phenotype, concurrent corticosteroid use, and previous mild sulfonamide reaction.
Remote and regional Australian populations may face limited access to alternative antimicrobials, making careful allergy classification and desensitisation pathways essential.

Introduction & Australian Epidemiology

Sulfonamide allergy refers to hypersensitivity reactions to sulfonamide-containing medications, ranging from mild cutaneous eruptions to severe, life-threatening dermatological and systemic reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The term most commonly applies to reactions triggered by sulfonamide antibiotics — primarily co-trimoxazole (trimethoprim–sulfamethoxazole) — but historically has been used more broadly to encompass structurally related non-antibiotic sulfonamides.

In Australia, self-reported sulfa allergy prevalence ranges from 3–6% of the general population, making it one of the most commonly documented drug allergies in medical records. Co-trimoxazole is widely prescribed in primary care for urinary tract infections, skin and soft tissue infections, and as prophylaxis against Pneumocystis jirovecii pneumonia (PJP) in immunocompromised individuals. The Australian Commission on Safety and Quality in Health Care (ACSQHC) has identified drug allergy documentation as a key safety priority under the National Safety and Quality Health Service (NSQHS) Standards.

Studies suggest that up to 90% of patients labelled with "sulfonamide allergy" do not have a true immunologically mediated reaction upon formal evaluation, yet the label persists and may result in the use of less effective, broader-spectrum, or more toxic alternatives. Accurate classification of the reaction type is essential to optimise antimicrobial stewardship and patient outcomes across Australian healthcare settings.

⚠️

Safety alert: Never dismiss patient-reported sulfonamide reactions without thorough clinical assessment. Even mild initial presentations can precede severe delayed reactions, and patients with HIV/AIDS, organ transplant recipients, and those on myelosuppressive chemotherapy carry significantly elevated risk of severe cutaneous adverse reactions (SCARs) to sulfonamides.

Mechanisms of Reaction

Understanding the immunological mechanisms underlying sulfonamide hypersensitivity is essential for accurate diagnosis, risk stratification, and safe therapeutic planning. Sulfonamide reactions involve multiple immunological pathways and non-immunological mechanisms.

The Arylamine Hypothesis

The predominant immunological mechanism for sulfonamide antibiotic reactions involves metabolic activation of the arylamine moiety present in sulfonamide antibiotics (e.g., sulfamethoxazole). Cytochrome P450 enzymes (particularly CYP2C9 and CYP3A4) convert the arylamine group to reactive hydroxylamine and nitroso intermediates. These metabolites act as haptens, covalently binding to endogenous proteins and forming immunogenic neoantigens that activate both humoral and cell-mediated immune responses.

This mechanism explains why sulfonamide antibiotics carry a substantially higher risk of hypersensitivity compared to non-antibiotic sulfonamides (such as furosemide, celecoxib, or thiazide diuretics), which lack the arylamine group and undergo different metabolic pathways.

Gell–Coombs Classification of Sulfonamide Reactions

Type	Mechanism	Timing	Clinical Features
Type I (Immediate)	IgE-mediated mast cell degranulation	Minutes to hours	Urticaria, angioedema, anaphylaxis (rare with sulfonamides)
Type II (Cytotoxic)	IgG/IgM-mediated cytotoxicity	Hours to days	Haemolytic anaemia, thrombocytopenia, agranulocytosis
Type III (Immune complex)	Immune complex deposition	7–21 days	Serum sickness-like reaction, drug-induced vasculitis
Type IV (Delayed)	T-cell-mediated (most common)	7–14 days (up to 21 days)	Maculopapular exanthem, DRESS, SJS, TEN, fixed drug eruption

Type IV Subtypes in Sulfonamide Hypersensitivity

Type IVa (Th1-mediated): Maculopapular exanthema; IFN-γ-driven inflammation
Type IVb (Th2-mediated): Drug reaction with eosinophilia and systemic symptoms (DRESS); IL-4, IL-5, IL-13 involvement
Type IVc (Cytotoxic T-cell): SJS and TEN; perforin/granzyme B-mediated keratinocyte apoptosis
Type IVd (Neutrophilic): Acute generalised exanthematous pustulosis (AGEP); IL-8/CXCL8-mediated neutrophil recruitment

Non-Immunological Mechanisms

Some adverse effects of sulfonamides are not mediated by immune mechanisms:

Dose-related toxicity: Hyperkalaemia (from trimethoprim inhibition of ENaC channels), crystalluria, kernicterus in neonates
Competitive antagonism: Sulfonamides competitively inhibit folate synthesis in susceptible organisms; in humans, this may cause megaloblastic anaemia with prolonged high-dose use
Pharmacogenomic predisposition: Slow N-acetyltransferase 2 (NAT2) acetylator phenotype results in accumulation of reactive metabolites, increasing risk of hypersensitivity

Genetic Risk Factors

HLA associations with sulfonamide hypersensitivity have been identified in various populations. HLA-B*38:02 has been associated with co-trimoxazole-induced SCARs in European populations. Pharmacogenomic testing is not yet standard of care in Australia but may become relevant for high-risk populations as precision medicine advances.

Clinical Presentations

Sulfonamide hypersensitivity manifests across a broad clinical spectrum. Accurate characterisation of the presenting reaction is critical for determining safety of future sulfonamide exposure and guiding allergy documentation.

Mild

Delayed Maculopapular Exanthem

Symmetric morbilliform eruption, mild pruritus, low-grade fever. Most common presentation (50–60% of reactions). Usually self-limiting upon drug withdrawal.

Setting: General practice / outpatient

Moderate

DRESS / Serum Sickness

Fever, facial oedema, lymphadenopathy, eosinophilia, hepatitis, interstitial nephritis. Onset 2–6 weeks. May require systemic corticosteroids and prolonged monitoring.

Setting: Hospital admission

Severe

SJS / TEN

Widespread epidermal necrosis, mucosal involvement, Nikolsky sign positive, detachment <10% BSA (SJS) or >30% BSA (TEN). Mortality 10–50%. Requires ICU/ burns unit.

Setting: ICU / Burns unit — immediate transfer

Detailed Clinical Manifestations

Mild Reactions

Delayed maculopapular exanthem: Onset typically 7–14 days after commencing therapy; morbilliform, symmetric, pruritic eruption often beginning on the trunk. May be accompanied by low-grade fever. Resolves within 7–14 days of drug cessation.
Fixed drug eruption: Well-demarcated, round, erythematous to violaceous plaques recurring at the same anatomical site upon re-exposure. Mucosal surfaces may be affected. Occurs within 30 minutes to 8 hours of re-exposure.
Isolated urticaria: True IgE-mediated urticaria to sulfonamides is uncommon. Most urticarial presentations represent a manifestation of a Type IV reaction.

Moderate Reactions

Drug reaction with eosinophilia and systemic symptoms (DRESS): Characterised by the triad of extensive cutaneous eruption, haematological abnormalities (eosinophilia, atypical lymphocytosis), and internal organ involvement (hepatitis, nephritis, pneumonitis, myocarditis). Onset 2–6 weeks after initiation; may flare for weeks after drug cessation. Mortality 5–10%, primarily from hepatic necrosis.
Serum sickness-like reaction: Fever, arthralgia, urticaria, and lymphadenopathy occurring 7–21 days after exposure. Unlike true serum sickness, immune complex deposition is typically absent.
Acute generalised exanthematous pustulosis (AGEP): Acute onset of widespread sterile pustules on erythematous background, fever, neutrophilia. Usually resolves within 2 weeks of drug withdrawal.

Severe Reactions — Requiring Emergency Management

🚨

Stevens-Johnson syndrome / Toxic epidermal necrolysis: SJS and TEN represent a severity continuum of epidermal necrolysis. SJS involves <10% body surface area (BSA) detachment; SJS/TEN overlap 10–30% BSA; TEN >30% BSA. Mucosal involvement (oral, conjunctival, genital, respiratory) is universal. Sulfonamides are among the most common drug triggers globally. SCORTEN severity scoring should be calculated on admission.

Prodrome of fever, malaise, stinging eyes, painful swallowing 1–3 days before rash onset
Dusky erythematous macules and targetoid lesions progressing to epidermal detachment
Nikolsky sign positive (lateral pressure causes epidermal sliding)
Haemorrhagic crusting of lips; conjunctival injection, pseudomembrane formation
Immediate withdrawal of all suspected drugs, referral to burns unit/ICU

Organ-Specific Non-Cutaneous Reactions

Haematological: Haemolytic anaemia (Coombs-positive), thrombocytopenia, agranulocytosis, methaemoglobinaemia
Hepatic: Cholestatic or hepatocellular hepatitis, particularly in DRESS
Renal: Acute interstitial nephritis, crystalluria with inadequate hydration
Pulmonary: Eosinophilic pneumonia, pulmonary infiltrates
Neurological: Aseptic meningitis (rare, particularly with trimethoprim component)

Cross-Reactivity

Cross-reactivity between sulfonamide antibiotics and other sulfonamide-containing or sulfite-containing medications is a common clinical concern, yet the evidence overwhelmingly indicates that true cross-reactivity is exceedingly rare.

Sulfonamide Antibiotics vs Non-Antibiotic Sulfonamides

Feature	Antibiotic Sulfonamides	Non-Antibiotic Sulfonamides
Examples	Sulfamethoxazole, sulfadiazine, sulfadoxine, sulfasalazine	Celecoxib, furosemide, thiazide diuretics, sumatriptan, topiramate, dorzolamide, probenecid
Arylamine group	Present — primary determinant of immunogenicity	Absent
Reactive metabolite formation	Yes (hydroxylamine, nitroso via CYP2C9/3A4)	No
Cross-reactivity risk	Between sulfonamide antibiotics: moderate (3–40% in some studies)	Extremely low (<1%); not clinically significant

✅

Key evidence: Strom et al. (2003) in the New England Journal of Medicine demonstrated that patients with prior sulfonamide antibiotic allergy had no increased risk of allergic reaction to non-antibiotic sulfonamides compared to penicillin-allergic controls. The risk is driven by a general predisposition to drug allergy, not chemical cross-reactivity.

Cross-Reactivity Among Sulfonamide Antibiotics

Cross-reactivity between different sulfonamide antibiotics (e.g., sulfamethoxazole and sulfadiazine) is more plausible, as they share the arylamine group and similar metabolic pathways. Studies suggest cross-reactivity rates of 3–40%, though methodological limitations make precise estimates difficult.

Sulfites — A Common Misconception

Sulfites (sodium metabisulfite, sulfur dioxide) used as preservatives in foods and medications are not structurally related to sulfonamides. Patients with sulfonamide allergy do not have an increased risk of sulfite sensitivity. Sulfite reactions are typically respiratory (bronchospasm in asthmatics) and are mediated by a completely different mechanism.

Clinical Recommendations for Cross-Reactivity Assessment

1

Classify the allergy

Determine if the reaction was to a sulfonamide antibiotic (with arylamine) or a non-antibiotic sulfonamide. If the latter, the allergy label does not imply cross-reactivity with other sulfonamide classes.

2

Assess severity

History of SCARs (SJS/TEN/DRESS) to any sulfonamide antibiotic warrants extreme caution with all sulfonamide antibiotics. Mild maculopapular reactions allow more flexibility.

3

Non-antibiotic sulfonamides are generally safe

Patients with sulfonamide antibiotic allergy can generally safely receive celecoxib, furosemide, thiazides, sumatriptan, topiramate, and other non-antibiotic sulfonamides. Document this clearly.

4

Consider supervised challenge

For patients requiring co-trimoxazole with unclear allergy history, graded oral challenge under specialist supervision may be appropriate (see Management & Alternatives).

Management & Alternatives

Management of sulfonamide allergy involves acute treatment of the reaction, accurate allergy documentation, selection of appropriate therapeutic alternatives, and consideration of desensitisation when sulfonamide therapy is clinically necessary.

Acute Management of Sulfonamide Hypersensitivity

Immediate

Cease all suspected sulfonamide-containing medications. Assess reaction severity (mild cutaneous vs SCARs). Provide supportive care: antihistamines for urticaria, topical emollients for exanthems. For SJS/TEN: fluid resuscitation, wound care, eye care — consider IV immunoglobulin or cyclosporine.

24–72 hours

Monitor for progression. For DRESS: check FBC, LFTs, renal function, troponin. Consider short-course systemic corticosteroids for moderate-to-severe reactions. Ensure the drug allergy is documented in all systems.

2–6 weeks

Follow-up assessment. Referral to clinical immunology/allergy specialist for formal evaluation. DRESS may relapse on tapering corticosteroids — prolonged monitoring advised.

Post-recovery

Formal allergy documentation with reaction type, severity, and date. Provide written allergy card. Update My Health Record. Referral for consideration of skin testing or desensitisation if sulfonamide therapy may be needed in future.

Therapeutic Alternatives by Clinical Indication

Urinary Tract Infection (Uncomplicated)

💊

Nitrofurantoin

Macrobid® · Macrodantin® · Nitrofurantoin · Antibiotic

Adult dose 100 mg PO BD (modified-release) or 50 mg PO QID (crystal/macro) for 5 days

Paediatric dose 1–2 mg/kg/dose PO QID for 5 days (minimum age 1 month; avoid if eGFR <45)

Renal adjustment Avoid if eGFR <45 mL/min (reduced efficacy, risk of peripheral neuropathy)

PBS status ✔ PBS General Benefit

💊

Cefalexin

Keflex® · Cefalexin · First-generation cephalosporin

Adult dose 500 mg PO BD for 5 days

Paediatric dose 12.5–25 mg/kg/dose PO BD–TDS (max 1 g/dose)

Renal adjustment eGFR <30: 250 mg PO TDS–QID; dialysis: 250–500 mg PO daily

PBS status ✔ PBS General Benefit

Pneumocystis jirovecii Pneumonia Prophylaxis

Co-trimoxazole is the gold-standard PJP prophylactic agent. When true sulfonamide allergy exists, the following alternatives are used:

💊

Dapsone

Dapsone · Sulfone antibiotic

Adult dose 100 mg PO daily (PJP prophylaxis)

Paediatric dose 1–2 mg/kg/dose PO daily (max 100 mg)

Key considerations Check G6PD status before commencing (risk of haemolytic anaemia). Cross-reactivity with sulfonamide antibiotics: ~3%. Methaemoglobinaemia risk.

PBS status ⚠ PBS Restricted Benefit

💊

Atovaquone

Mepron® · Atovaquone · Hydroxynaphthoquinone

Adult dose 1500 mg PO daily with food (PJP prophylaxis)

Paediatric dose 30 mg/kg PO daily with food (1–3 months: 30 mg/kg; 4–24 months: 45 mg/kg)

Key considerations Better tolerated than dapsone. No G6PD requirement. No bone marrow suppression. Lower efficacy than co-trimoxazole in some studies.

PBS status ✖ Not PBS

💊

Pentamidine (inhaled)

Pentamidine · Pentamidine isethionate · Diamidine

Adult dose 300 mg nebulised monthly (PJP prophylaxis)

Key considerations Reserve for patients intolerant of both co-trimoxazole and dapsone. Does not protect against toxoplasmosis. Bronchospasm risk — pre-treat with bronchodilator.

PBS status ✖ Not PBS (Special Access Scheme)

Toxoplasmosis Prophylaxis

Co-trimoxazole also provides concurrent Toxoplasma gondii prophylaxis. If sulfonamide allergy precludes co-trimoxazole, add pyrimethamine + leucovorin to the alternative PJP prophylaxis regimen:

Pyrimethamine: 25–50 mg PO weekly + leucovorin 25 mg PO weekly (to prevent myelosuppression)
Monitor FBC fortnightly for first month, then monthly

Desensitisation Protocols

Drug desensitisation may be considered when sulfonamide therapy is essential and no suitable alternative exists. This procedure should only be undertaken in a supervised hospital setting with resuscitation capabilities.

⚠️

Contraindications to desensitisation: Prior SJS, TEN, DRESS, or AGEP to sulfonamides. Desensitisation is only appropriate for patients with non-severe (mild-to-moderate) Type I or delayed exanthematous reactions. SCAR history is an absolute contraindication.

Rapid Oral Desensitisation Protocol (Modified Trimethoprim–Sulfamethoxazole)

The following is a commonly used 12-step protocol adapted from Australian and international immunology references:

Step	SMX dose (mg)	Cumulative SMX (mg)	Interval
1	0.02	0.02	15 min
2	0.04	0.06	15 min
3	0.1	0.16	15 min
4	0.2	0.36	15 min
5	0.4	0.76	15 min
6	1	1.76	15 min
7	2	3.76	15 min
8	5	8.76	15 min
9	10	18.76	15 min
10	25	43.76	15 min
11	50	93.76	15 min
12	160 (full dose)	253.76	—

Each dose is diluted in water or administered as oral suspension. Continuous cardiac monitoring and IV access should be maintained. If a reaction occurs at any step, treat the reaction and consider repeating the same dose or the previous tolerated dose.

Allergy Documentation & Discharge Planning

Document the specific sulfonamide drug, dose, route, date, and detailed reaction description
Classify as: mild (non-SCAR) vs severe (SCAR) — this distinction is critical for future management
Specify which sulfonamide-containing medications are and are not safe (e.g., "Allergy to sulfamethoxazole — may use celecoxib, furosemide safely")
Update My Health Record Shared Health Summary
Provide patient with a written allergy card for presentation at all healthcare encounters
For hospitalised patients: alert pharmacy, nursing, and all treating teams
Refer to clinical immunology/allergy for formal evaluation if not already completed

Special Populations

🤰 Pregnancy

Co-trimoxazole

Contraindicated in first trimester and at term (folate antagonism, kernicterus risk). May be used in second trimester if benefit outweighs risk.

Nitrofurantoin

Safe for UTI treatment in pregnancy (avoid at term). Suitable alternative if sulfonamide-allergic.

Cefalexin

Category A (TGA). Safe in pregnancy. Preferred alternative for UTI in sulfonamide allergy.

Dapsone

Category B3. Avoid unless no alternative. G6PD testing essential.

👶 Paediatrics

Co-trimoxazole

Widely used in children >6 weeks. Neonates: kernicterus risk due to bilirubin displacement. Dose: 2–4 mg/kg SMX component PO BD.

Alternatives

Cefalexin (UTI), atovaquone (PJP prophylaxis), dapsone (if G6PD normal) are preferred paediatric alternatives.

PJP prophylaxis

HIV-exposed infants require PJP prophylaxis from age 4–6 weeks. Atovaquone or dapsone are alternatives if sulfonamide-allergic.

👴 Elderly

Co-trimoxazole

Higher risk of hyperkalaemia (trimethoprim-mediated ENaC blockade), particularly with ACEi/ARB/spironolactone. Monitor K⁺ within 3 days.

Renal impairment

Age-related renal decline necessitates dose adjustment. eGFR <30: avoid co-trimoxazole unless dose-adjusted.

Polypharmacy

Review all sulfonamide-containing medications. Elderly patients are more likely to be on thiazides, furosemide — reassure that cross-reactivity risk is negligible.

🛡️ Immunocompromised

HIV/AIDS

Highest risk population for sulfonamide reactions (up to 40–60% incidence with CD4 <200). Re-challenge and desensitisation are common strategies due to limited alternatives.

Transplant recipients

PJP prophylaxis essential. Consider atovaquone or dapsone if sulfonamide-allergic. Drug interactions with calcineurin inhibitors must be reviewed.

DRESS risk

Immunosuppressed patients may have atypical or delayed DRESS presentations. Maintain high index of suspicion for 2–8 weeks post-exposure.

🫘 Renal Impairment

Co-trimoxazole

Dose adjust for eGFR 15–30: reduce by 50%. eGFR <15: avoid. Monitor for hyperkalaemia, rising creatinine.

Nitrofurantoin

Contraindicated if eGFR <45 (inadequate urinary concentration, peripheral neuropathy risk).

Haemodialysis

Sulfamethoxazole is partially removed by haemodialysis. Dose after dialysis sessions. Atovaquone is not dialysed.

🫁 Hepatic Impairment

Sulfamethoxazole

Hepatically metabolised. Severe hepatic impairment: increased risk of hepatotoxicity. Monitor LFTs closely. Consider dose reduction.

DRESS with hepatitis

If DRESS includes significant hepatitis, avoid all sulfonamide antibiotics permanently. Document as SCAR allergy.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Higher burden of infectious disease

Aboriginal and Torres Strait Islander peoples experience significantly higher rates of skin and soft tissue infections, otitis media, respiratory infections, and rheumatic heart disease — conditions for which co-trimoxazole is frequently prescribed. Sulfonamide allergy management must account for the clinical necessity of these agents.

Remote and rural access

Many communities in remote Northern Territory, Western Australia, and Queensland have limited pharmacy access and a restricted formulary. Alternative agents (e.g., nitrofurantoin, atovaquone) may be unavailable. Telehealth allergy review and desensitisation pathway planning with specialist support are essential.

CA-MRSA considerations

Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) prevalence is markedly higher in Indigenous communities. Co-trimoxazole is a key oral agent for CA-MRSA skin infections — accurate sulfonamide allergy classification avoids unnecessary escalation to intravenous vancomycin or linezolid.

Rheumatic heart disease (RHD)

Secondary prophylaxis for RHD primarily uses benzathine penicillin G. However, co-trimoxazole may be considered for patients with penicillin allergy. If sulfonamide allergy is also present, specialist input from RHDAustralia and infectious disease teams is required.

G6PD deficiency prevalence

G6PD deficiency affects 5–15% of some Aboriginal and Torres Strait Islander populations. Dapsone, a key sulfonamide allergy alternative for PJP prophylaxis, requires pre-treatment G6PD testing. Point-of-care G6PD testing availability is expanding in remote NT and WA.

Cultural safety and allergy documentation

Language barriers, health literacy, and fragmented health records may result in incomplete allergy documentation across multiple health services. Use of My Health Record, culturally appropriate allergy education materials, and Aboriginal Health Worker/Practitioner involvement in allergy counselling improves safety.

Stewardship implications

Inaccurate sulfonamide allergy labels in Indigenous patients may drive use of broader-spectrum antibiotics (e.g., fluoroquinolones, extended-spectrum cephalosporins), contributing to antimicrobial resistance in communities already disproportionately affected by resistant organisms.

Investigations

Investigation of suspected sulfonamide hypersensitivity combines clinical history, laboratory testing, and in selected cases, specialist allergy testing. There is no single confirmatory test for sulfonamide allergy.

Essential

Detailed drug reaction history

Specific drug, dose, timing, symptom description, duration, treatment required, and prior re-exposures. MBS Item 132 — GP consultation.

Available

Full blood count (FBC)

Eosinophilia supports drug hypersensitivity (especially DRESS). Atypical lymphocytes may be present. MBS Item 65070.

Available

Liver function tests (LFTs)

Essential if DRESS suspected (hepatitis in 60–80% of DRESS cases). MBS Item 66500.

Available

Renal function & urinalysis

Screen for interstitial nephritis (rising creatinine, sterile pyuria, eosinophiluria). MBS Item 66500.

Available

G6PD assay

Required before commencing dapsone as an alternative. Available in most Australian laboratories. MBS Item 66600.

Available

Serum tryptase (if anaphylaxis suspected)

Collect within 1–2 hours of symptom onset. Baseline tryptase at 24 hours for comparison. MBS Item 65120.

Referral

Skin prick testing (SPT) / Intradermal testing (IDT)

Limited role for sulfonamides — low sensitivity and not standardised in Australia. Referral to clinical immunology/allergy specialist. MBS Item 12000/12001 if performed by specialist.

Specialist

Lymphocyte transformation test (LTT)

Research and tertiary centre tool. Measures drug-specific T-cell proliferation. Available at select immunology laboratories (e.g., Royal Adelaide Hospital, Westmead Hospital). Not routinely MBS-rebated.

Specialist

Patch testing

May support diagnosis of delayed-type reactions (exanthem, DRESS). Sensitivity ~50–70%. Performed by specialist dermatology/allergy units.

Referral

Graded oral provocation challenge

Gold standard for excluding drug allergy. Only in hospital setting with resuscitation capability. Indicated when allergy history is unclear and sulfonamide therapy is needed. Specialist-performed.

📚 References

1. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349(17):1628-1635.
2. Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24(7):856-870.
3. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
4. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med. 1989;110(4):286-289.
5. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2022. Available at: immunisationhandbook.health.gov.au.
6. Australian Indigenous HealthInfoNet. Summary of Aboriginal and Torres Strait Islander health. Perth: Edith Cowan University; 2023.
7. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387-1397.
8. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int. 2006;55(1):1-8.
9. Sullivan TJ, Ong YC, Gilliam LK. Studies of the multiple drug allergy syndrome. J Allergy Clin Immunol. 1989;83(1):198-207.
10. Royal Australian College of General Practitioners (RACGP). Prescribing drugs of dependence in general practice, Part A: Antibiotics. Melbourne: RACGP; 2023.
11. Australasian Society of Clinical Immunology and Allergy (ASCIA). Drug allergy — clinical update. Sydney: ASCIA; 2023. Available at: allergy.org.au.
12. AIHW (Australian Institute of Health and Welfare). Aboriginal and Torres Strait Islander health performance framework 2023 summary report. Canberra: AIHW; 2023.
13. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183-198.
14. Trubiano JA, Worth LJ, Urbancic K, et al. Return to sender: the need to re-address patient antibiotic allergy labels in Australia. Intern Med J. 2016;46(11):1311-1317.